Pages that link to "Q36012089"

The following pages link to The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease (Q36012089):

Displaying 23 items.

• A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD) (Q24612655) (← links)
• Exploring myelin dysfunction in multiple system atrophy (Q26852634) (← links)
• Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene (Q27334656) (← links)
• The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease (Q28087330) (← links)
• An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity (Q33317678) (← links)
• The many faces of α-synuclein: from structure and toxicity to therapeutic target (Q34972009) (← links)
• Autophagy in dementias (Q35624697) (← links)
• Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells (Q36202906) (← links)
• Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. (Q37152191) (← links)
• Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders (Q37249765) (← links)
• Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. (Q37447970) (← links)
• Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. (Q37694473) (← links)
• A new perspective in Parkinson’s disease, chaperone-mediated autophagy (Q37826859) (← links)
• Examining the mechanisms that link β-amyloid and α-synuclein pathologies (Q38006559) (← links)
• Synucleinopathies: common features and hippocampal manifestations (Q39003423) (← links)
• Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). (Q39803583) (← links)
• Protein expression is altered during spontaneous sleep in aged Sprague Dawley rats (Q41944249) (← links)
• Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease (Q48246699) (← links)
• Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation (Q48426203) (← links)
• AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers (Q50279712) (← links)
• Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease (Q51671122) (← links)
• Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein (Q90497044) (← links)
• CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects (Q102220321) (← links)